Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Effectiveness of BCMA-GPRC5D CAR-T in Relapsed/Refractory Multiple Myeloma
NCT07195617Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells
01
Overview
Open-label, single-arm trial of Ori-CAR-002 in multiple myeloma (MM), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoint: Safety assessment at 24 months. Planned start Oct 2025; status: withdrawn.
02
Drugs
Ori-CAR-002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07195617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195617.